Please use this identifier to cite or link to this item:
Title: Prospective association of liver function biomarkers with development of hepatobiliary cancers.
Authors: Stepien, Magdalena
Fedirko, Veronika
Duarte-Salles, Talita
Ferrari, Pietro
Freisling, Heinz
Trepo, Elisabeth
Trichopoulou, Antonia
Bamia, Christina
Weiderpass, Elisabete
Olsen, Anja
Tjønneland, Anne
Overvad, Kim
Boutron-Ruault, Marie-Christine
Fagherazzi, Guy
Racine, Antoine
Kühn, Tilman
Kaaks, Rudolf
Aleksandrova, Krasimira
Boeing, Heiner
Lagiou, Pagona
Benetou, Vassiliki
Trichopoulos, Dimitrios
Palli, Domenico
Grioni, Sara
Tumino, Rosario
Naccarati, Alessio
Panico, Salvatore
Bueno-de-Mesquita, H Bas
Peeters, Petra H
Lund, Eiliv
Quirós, J Ramón
Nápoles, Osmel Companioni
Sánchez, María-José
Dorronsoro, Miren
Huerta, José María
Ardanaz, Eva
Ohlsson, Bodil
Sjöberg, Klas
Werner, Mårten
Nystrom, Hanna
Khaw, Kay-Tee
Key, Timothy J
Gunter, Marc
Cross, Amanda
Riboli, Elio
Romieu, Isabelle
Jenab, Mazda
Keywords: Biological markers;Hepatobiliary cancer;Liver function test;Nested case-control study;Prospective cohort
metadata.dc.subject.mesh: Adult
Aged, 80 and over
Alanine Transaminase
Alkaline Phosphatase
Aspartate Aminotransferases
Bile Duct Neoplasms
Biliary Tract Neoplasms
Carcinoma, Hepatocellular
Case-Control Studies
Liver Function Tests
Liver Neoplasms
Middle Aged
Prospective Studies
Risk Factors
Young Adult
Issue Date: 11-Jan-2016
Abstract: Serum liver biomarkers (gamma-glutamyl transferase, GGT; alanine aminotransferase, ALT; aspartate aminotransferase, AST; alkaline phosphatase, ALP; total bilirubin) are used as indicators of liver disease, but there is currently little data on their prospective association with risk of hepatobiliary cancers. A nested-case control study was conducted within the prospective EPIC cohort (>520,000 participants, 10 European countries). After a mean 7.5 mean years of follow-up, 121 hepatocellular carcinoma (HCC), 34 intrahepatic bile duct (IHBC) and 131 gallbladder and biliary tract (GBTC) cases were identified and matched to 2 controls each. Circulating biomarkers were measured in serum taken at recruitment into the cohort, prior to cancer diagnosis. Multivariable adjusted conditional logistic regression was used to calculate odds ratios and 95% confidence intervals (OR; 95%CI). In multivariable models, 1SD increase of each log-transformed biomarker was positively associated with HCC risk (OR(GGT)=4.23, 95%CI:2.72-6.59; OR(ALP)=3.43, 95%CI:2.31-5.10;OR(AST)=3.00, 95%CI:2.04-4.42; OR(ALT)=2.69, 95%CI:1.89-3.84; OR(Bilirubin)=2.25, 95%CI:1.58-3.20). Each liver enzyme (OR(GGT)=4.98; 95%CI:1.75-14.17; OR(AST)=3.10, 95%CI:1.04-9.30; OR(ALT)=2.86, 95%CI:1.26-6.48, OR(ALP)=2.31, 95%CI:1.10-4.86) but not bilirubin (OR(Bilirubin)=1.46,95%CI:0.85-2.51) showed a significant association with IHBC. Only ALP was significantly associated with GBTC risk (OR(ALP)=1.59, 95%CI:1.20-2.09). This study shows positive associations between circulating liver biomarkers in sera collected prior to cancer diagnoses and the risks of developing HCC or IHBC, but not GBTC.
metadata.dc.identifier.doi: 10.1016/j.canep.2016.01.002
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons